Cargando…

Challenges associated with limited‐resources cancer care facility: Bilateral breast myeloid sarcoma as an example

Myeloid sarcoma (MS) is a rare myeloid malignancy. It can arise before, concurrent with, or following different malignant hematological diseases, most commonly acute myeloid leukemia (AML), myelodysplastic syndrome, or myeloproliferative neoplasms. Here we describe a 30‐year‐old female with AML‐M1 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Khoshnaw, Najmaddin, Yassin, Ahmed K., Alwan, Alaa F., Hassan, Hemin A., Mula‐Hussain, Layth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878049/
https://www.ncbi.nlm.nih.gov/pubmed/31788245
http://dx.doi.org/10.1002/ccr3.2407
Descripción
Sumario:Myeloid sarcoma (MS) is a rare myeloid malignancy. It can arise before, concurrent with, or following different malignant hematological diseases, most commonly acute myeloid leukemia (AML), myelodysplastic syndrome, or myeloproliferative neoplasms. Here we describe a 30‐year‐old female with AML‐M1 who presented to the hematology department with bilateral breast pain and tenderness. Available diagnostic measures including ultrasound of breast and magnetic resonance imaging were used to determine the nature of these breast lumps. MS was definitively diagnosed via biopsy and the patient was treated with systemic chemotherapy. Despite her AML treatment she unfortunately died secondary to disease progression. The authors consider this case of particular educational value due to the bilateral and aggressive nature of this patient’s disease in the setting of a cancer‐care facility with limited resources. KEY CLINICAL MESSAGE: In retrospect, if breast MS had been considered earlier in this patient’s presentation, a referral to an outside center with matched stem cell transplantation capability may have been warranted after complete remission following first bone marrow relapse, rather than continuing chemotherapy alone.